Bellevue Group’s CureVac CVAC Stock Holding History

Bellevue Group’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-120	Closed	-$1K	–	198
2021 Q3	$1K	Buy	120 +50	+71%	+$3.01K	﹤0.01%	220
2021 Q2	$39K	Buy	+70	New	+$7K	﹤0.01%	214

Other funds holding CVAC

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Bellevue Group's CVAC Position: Q4 2021 in Review

Bellevue Group sold out of CureVac (CVAC) in Q4 2021, closing a stake of 35,200 shares — an estimated $1.92M sold.

Bellevue Group first reported a position in CVAC in Q3 2020 and held it in 4 quarters. The position peaked at $2.64M in Q1 2021. 103 funds tracked by Wall St. Rank hold CVAC as of Q4 2021.

Bellevue Group reported no remaining CureVac position as of Q4 2021 after selling out during the quarter.
Bellevue Group sold 35,200 CureVac shares in Q4 2021, an estimated $1.92M.
Bellevue Group first reported a position in CureVac in Q3 2020 and held it in 4 quarters.
Bellevue Group's CureVac position peaked at $2.64M in Q1 2021.
103 funds tracked by Wall St. Rank held CureVac as of Q4 2021.

Based on Bellevue Group's 13F filing for Q4 2021, filed 10 Feb 2022.